Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease

Neuroreport. 2006 May 15;17(7):705-9. doi: 10.1097/01.wnr.0000215769.71657.65.

Abstract

Recently, we confirmed the presence of enhanced neural reconstruction in Parkinson's disease and in an animal model of Parkinson's disease based on increased polysialic acid-like immunoreactivity. Changes in neurogenesis often appear parallel to changes in angiogenesis. Moreover, both these processes share similar modulating factors, like vascular endothelial growth factor (VEGF) and its receptors VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1). Using immunohistochemistry, we identified in this study upregulation of VEGF in the substantia nigra but not in the striatum of patients with Parkinson's disease by enzyme-linked immunosorbent assay. Such overexpression may participate in vascular remodeling and neurogenesis in the substantia nigra of Parkinson's disease.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Brain / metabolism*
  • Case-Control Studies
  • Diagnostic Imaging / methods
  • Enzyme-Linked Immunosorbent Assay / methods
  • Female
  • Glial Fibrillary Acidic Protein / metabolism
  • Humans
  • Immunohistochemistry / methods
  • Male
  • Middle Aged
  • Parkinson Disease / metabolism*
  • Receptors, Vascular Endothelial Growth Factor / classification
  • Receptors, Vascular Endothelial Growth Factor / metabolism*
  • Statistics, Nonparametric
  • Vascular Endothelial Growth Factor A / classification
  • Vascular Endothelial Growth Factor A / metabolism*

Substances

  • Glial Fibrillary Acidic Protein
  • Vascular Endothelial Growth Factor A
  • Receptors, Vascular Endothelial Growth Factor